Wealth Enhancement Trust Services’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-49
Closed -$954 – 1212
2026
Q2
$954 Buy
+49
New +$888 ﹤0.01% 1140

Other funds holding MLTX

Wealth Enhancement Trust Services's MLTX Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 49 shares — an estimated $954 sold.

Wealth Enhancement Trust Services first reported a position in MLTX in Q2 2026 and held it in 1 quarter. The position peaked at $954 in Q2 2026. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 49 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $954.
  • Wealth Enhancement Trust Services first reported a position in MoonLake Immunotherapeutics in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's MoonLake Immunotherapeutics position peaked at $954 in Q2 2026.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.